

Oxytocin Formulation

Vers 1.12		Revision Date: 28.09.2024		S Number: 17263-00013	Date of last issue: 06.04.2024 Date of first issue: 26.09.2018					
Sect	Section 1: Identification									
	Produc	ct identifier	:	Oxytocin Formulation						
	Recom	nmended use of the c	hem	ical and restriction	ons on use					
		mended use tions on use	:	Veterinary produ Not applicable	ct					
	Restric		•							
	Manufa	acturer or supplier's	deta	ils						
	Compa	iny	:	MSD						
	Addres	S	:	50 Tuas West Dr Singapore - Sing						
	Teleph	one	:	+1-908-740-4000)					
	Emerge	ency telephone numbe	er :	65 6697 2111 (24	4/7/365)					
	E-mail	address	:	EHSDATASTEW	/ARD@msd.com					

Section 2: Hazard identification

Classification of the substance or mixture

Not a hazardous substance or mixture.

GHS Label elements, including precautionary statements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Oxytocin, monoacetate (salt)	6233-83-6	< 0.1

Section 4: First-aid measures

Description of necessary first-aid measures

:

If inhaled

If inhaled, remove to fresh air. Get medical attention if symptoms occur.



Oxytocin Formulation

ersion .12	Revision Date: 28.09.2024		0S Number: 47263-00013	Date of last issue: 06.04.2024 Date of first issue: 26.09.2018
In cas	se of skin contact	:		r and soap as a precaution. ention if symptoms occur.
In cas	se of eye contact	:	Flush eyes with	water as a precaution. ention if irritation develops and persists.
lf swa	allowed	:	If swallowed, DO Get medical atte	D NOT induce vomiting. ention if symptoms occur. proughly with water.
Most	important symptoms a	and	effects, both ac	ute and delayed
Risks Prote	ction of first-aiders	:	None known. No special preca	autions are necessary for first aid responders
Indic	ation of any immediate	me	dical attention a	and special treatment needed
Treat	ment	:	Treat symptoma	tically and supportively.
ection 5	: Fire-fighting measure	S		
E. dia				
	guishing media			
Suital	ble extinguishing media	:	Water spray Alcohol-resistan Carbon dioxide Dry chemical	
Unsu media	itable extinguishing a	:	None known.	
Spec	ial hazards arising from	n th	e substance or	mixture
-	ific hazards during fire-			nbustion products may be a hazard to health
Haza ucts	rdous combustion prod-	:	No hazardous c	ombustion products are known
Spec	ial protective actions for	or fi	re-fighters	
	ial protective equipment efighters	:	essary.	ined breathing apparatus for firefighting if neo otective equipment.
Speci ods	ific extinguishing meth-	:	cumstances and Use water spray	ng measures that are appropriate to local cir- d the surrounding environment. v to cool unopened containers. aged containers from fire area if it is safe to o

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures Personal precautions : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).



Oxytocin Formulation

Version 1.12	Revision Date: 28.09.2024	SDS Number: 3447263-00013	Date of last issue: 06.04.2024 Date of first issue: 26.09.2018					
	Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or of barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.							
	Methods and materials for containn Methods for cleaning up :		ing up inert absorbent material. s, provide dyking or other appropriate contain- material from spreading. If dyked material can tore recovered material in appropriate container. aining materials from spill with suitable absor- nal regulations may apply to releases and dis- naterial, as well as those materials and items he cleanup of releases. You will need to deter- gulations are applicable. nd 15 of this SDS provide information regarding r national requirements.					

Section 7: Handling and storage

Precautions for safe handling							
Technical measures :	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.						
Local/Total ventilation : Advice on safe handling :	Use only with adequate ventilation.						
Hygiene measures :	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.						
Conditions for safe storage, including any incompatibilities							
Conditions for safe storage : Materials to avoid :	Keep in properly labelled containers. Store in accordance with the particular national regulations. Do not store with the following product types:						
	Strong oxidizing agents						



Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.12	28.09.2024	3447263-00013	Date of first issue: 26.09.2018

Section 8: Exposure controls/personal protection

Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Oxytocin, monoacetate (salt)	6233-83-6	STEL	50 ng/m3 (OEB 5)	Internal
		Wipe limit	500 ng/100 cm ²	Internal

Appropriate engineering : control measures	Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to pre- vent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment tech- nology designed to prevent leakage of compounds into the workplace.
Individual protection measures	s, such as personal protective equipment (PPE)
Eye/face protection :	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. Work uniform or laboratory coat. Additional body garments should be used based upon the
	task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection :	No personal respiratory protective equipment normally re- quired.
Hand protection	yunou.
Material :	Chemical-resistant gloves
Remarks :	Consider double gloving.
ation 0. Dhusical and shaminal m	

Section 9: Physical and chemical properties

Appearance

```
: liquid
```



Oxytocin Formulation

Vers 1.12	ion	Revision Date: 28.09.2024		S Number: 7263-00013	Date of last issue: 06.04.2024 Date of first issue: 26.09.2018
	Colour		:	No data available	
	Odour		:	No data available	
		Threshold	:	No data available	
	рН		:	No data available	
	Melting	point/freezing point	:	No data available	
	Initial bo range	oiling point and boiling	:	No data available	
	Flash p	oint	:	No data available	
	Evapora	ation rate	:	No data available	9
	Flamma	ability (solid, gas)	:	Not applicable	
	Flamma	ability (liquids)	:	No data available)
		explosion limit / Upper bility limit	:	No data available)
		explosion limit / Lower bility limit	:	No data available	
	Vapour	pressure	:	No data available)
	Relative	e vapour density	:	No data available	9
	Relative	e density	:	No data available	9
	Density		:	No data available	9
	Solubili Wate	ty(ies) er solubility	:	No data available	
		n coefficient: n-	:	Not applicable	
	octanol/ Auto-igi	/water nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	Viscosii Visc	ty osity, kinematic	:	No data available	9
	Explosi	ve properties	:	Not explosive	
	Oxidizir	ng properties	:	The substance of	r mixture is not classified as oxidizing.



Oxytocin Formulation

rsion 2	Revision Date: 28.09.2024	-	9S Number: 47263-00013	Date of last issue: 06.04.2024 Date of first issue: 26.09.2018
Moleo	cular weight	:	No data availabl	e
	cle characteristics cle size	:	Not applicable	
ction 1	0: Stability and reactive	ity		
Possi tions Cond Incon	nical stability bility of hazardous reac- itions to avoid npatible materials rdous decomposition	:	Stable under nor Can react with s None known. Oxidizing agents	rong oxidizing agents.
ction 1	1: Toxicological inform	natio	on	
Inforr expos	nation on likely routes of sure	:	Inhalation Skin contact Ingestion Eye contact	
	e toxicity lassified based on availa	able	information.	
Com	ponents:			
-	ocin, monoacetate (sal	t): :	LD50 (Mouse): >	514 mg/kg
			LD50 (Rat): > 21	mg/kg
	e toxicity (other routes of nistration)	:	LD50 (Mouse): > Application Route	
			LD50 (Mouse): 5. Application Route	
			LD50 (Rat): > 21 Application Route	
			LD50 (Rat): 2.3 n	ng/kg

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.



Oxytocin Formulation

/ersion .12	Revision Date: 28.09.2024	-	S Number: 47263-00013	Date of last issue: 06.04.2024 Date of first issue: 26.09.2018					
Resp	piratory or skin sensi	itisatio	n						
Skin	sensitisation								
	Not classified based on available information.								
Respiratory sensitisation Not classified based on available information.									
	n cell mutagenicity classified based on ava	ailable	information.						
<u>Com</u>	ponents:								
Oxyt	ocin, monoacetate (s	salt):							
Geno	otoxicity in vitro	:		omosomal aberration uman lymphocytes e					
	inogenicity lassified based on ava	ailable	information.						
-	oductive toxicity								
	lassified based on ava	ailable	information.						
Com	ponents:								
-	ocin, monoacetate (s	salt):		alanmant					
ment	ts on foetal develop-	•	Developmental	elopment ute: Subcutaneous Toxicity: NOAEL: 1 mg/kg body weight cts on foetal development					
Repro sessr	oductive toxicity - As- ment	:	May damage th	e unborn child.					
	F - single exposure lassified based on ava	ailable	information.						
	F - repeated exposur classified based on ava		information.						
Repe	eated dose toxicity								
Com	ponents:								
	ocin, monoacetate (s	salt):							
Spec LOAE Appli	ies	:	Rat 5 µg/kg Subcutaneous 5 Days						

Exposure time:5 DaysTarget Organs:Endocrine system



Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.12	28.09.2024	3447263-00013	Date of first issue: 26.09.2018

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Oxytocin, monoacetate (salt):	
Inhalation :	Target Organs: Central nervous system Symptoms: behavioral abnormalities Target Organs: Cardio-vascular system Symptoms: Increased heart rate, May cause cardiac arrhyth- mia., hypotension, tachycardia, flushing Target Organs: Gastrointestinal tract Symptoms: Nausea, Vomiting
Ingestion :	Target Organs: Central nervous system Symptoms: behavioral abnormalities Target Organs: Cardio-vascular system Symptoms: Increased heart rate, May cause cardiac arrhyth- mia., hypotension, tachycardia, flushing Target Organs: Gastrointestinal tract Symptoms: Nausea, Vomiting

Section 12: Ecological information

Toxicity	
Components:	
Oxytocin, monoacetate (salt):	
Ecotoxicology Assessment Acute aquatic toxicity :	Toxic effects cannot be excluded
Chronic aquatic toxicity :	Toxic effects cannot be excluded
Persistence and degradability No data available Bioaccumulative potential	
Components:	
Oxytocin, monoacetate (salt): Partition coefficient: n- : octanol/water	log Pow: 6.27
Mobility in soil No data available	
Other adverse effects No data available	



Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.12	28.09.2024	3447263-00013	Date of first issue: 26.09.2018

Section 13: Disposal considerations

Disposal methods		
Waste from residues	:	Do not dispose of waste into sewer.
Contaminated packaging	:	Dispose of in accordance with local regulations. Empty containers should be taken to an approved waste han-
		dling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG UN number UN proper shipping name Transport hazard class(es) Subsidiary risk Packing group Labels Environmentally hazardous	· · · ·	Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable no
IATA-DGR UN/ID No. UN proper shipping name Transport hazard class(es) Subsidiary risk Packing group Labels Packing instruction (cargo aircraft) Packing instruction (passen- ger aircraft)		Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable
IMDG-Code UN number UN proper shipping name Transport hazard class(es)	:	Not applicable Not applicable Not applicable

on proper snipping name	•	Not applicable
Transport hazard class(es)	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable



Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.12	28.09.2024	3447263-00013	Date of first issue: 26.09.2018

Section 15: Regulatory information

Safety, health and environmental regulations specific for the product in question

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations. Environmental Protection and Management Act and : Not applicable Environmental Protection and Management (Hazardous Substances) Regulations Fire Safety (Petroleum and Flammable Materials) : Not applicable Regulations The components of this product are reported in the following inventories: AICS not determined : DSL : not determined

IECSC	:	not determined

Section 16: Other information

Revision Date	:	28.09.2024
Further information		
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/
Date format	:	dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median



Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.12	28.09.2024	3447263-00013	Date of first issue: 26.09.2018

Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN